| 穆珺玉,李杰慧,秦 瑶,李 萌,冉 立.血清骨桥蛋白、胸苷激酶1、成纤维细胞生长因子受体4与局部晚期宫颈癌患者新辅助化疗疗效的关系研究[J].,2022,(18):3504-3508 |
| 血清骨桥蛋白、胸苷激酶1、成纤维细胞生长因子受体4与局部晚期宫颈癌患者新辅助化疗疗效的关系研究 |
| Relationship Study between Serum Osteopontin, Thymidine Kinase 1, Fibroblast Growth Factor Receptor 4 and Neoadjuvant Chemotherapy in Patients with Local Advanced Cervical Cancer |
| 投稿时间：2022-02-07 修订日期：2022-02-28 |
| DOI：10.13241/j.cnki.pmb.2022.18.019 |
| 中文关键词: 骨桥蛋白 胸苷激酶1 成纤维细胞生长因子受体4 局部晚期宫颈癌 新辅助化疗 |
| 英文关键词: Osteopontin Thymidine kinase 1 Fibroblast growth factor receptor 4 Local advanced cervical cancer Neoadjuvant chemotherapy |
| 基金项目:贵州省科技合作计划项目（20157382）；贵州省卫生健康委科学技术基金项目（gzwjkj2019-1-076） |
|
| 摘要点击次数: 956 |
| 全文下载次数: 475 |
| 中文摘要: |
| 摘要 目的：探讨血清骨桥蛋白（OPN）、胸苷激酶1（TK1）、成纤维细胞生长因子受体4（FGFR4）与局部晚期宫颈癌（LACC）患者新辅助化疗疗效的关系。方法：选择2011年8月至2019年7月贵州医科大学附属肿瘤医院收治的160例LACC患者，均接受3个周期的紫杉醇和卡铂新辅助化疗，根据疗效将患者分为有效组和无效组。化疗前检测血清OPN、TK1、FGFR4水平，比较两组上述指标差异。收集相关资料，以多因素Logistic回归分析LACC患者新辅助化疗疗效的影响因素。采用受试者工作特征（ROC）曲线分析OPN、TK1、FGFR4对新辅助化疗疗效的预测价值。结果：160例患者均顺利完成新辅助化疗，治疗有效129例（有效组），无效31例（无效组）。无效组血清OPN、TK1、FGFR4水平均高于有效组（P＜0.05）。多因素Logistic回归分析结果显示，FIGO分期为Ⅲ期、IVA期以及血清OPN、TK1、FGFR4水平较高是影响LACC患者新辅助化疗疗效的危险因素（P＜0.05）。血清OPN、TK1、FGFR4预测LACC患者新辅助化疗疗效的ROC曲线下面积分别为0.831、0.695、0.767，三项联合预测的曲线下面积为0.893，高于各指标单独检测。结论：LACC患者新辅助化疗疗效受到FIGO分期和血清OPN、TK1、FGFR4水平影响，联合检测血清OPN、TK1、FGFR4水平对LACC患者新辅助化疗疗效具有一定的预测价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum osteopontin (OPN), thymidine kinase 1 (TK1), fibroblasts growth factor receptor 4 (FGFR4) and neoadjuvant chemotherapy in patients with locally advanced cervical cancer (LACC). Methods: 160 patients with LACC who were treated in the Affiliated Tumor Hospital of Guizhou Medical University from August 2011 to July 2019 were selected. They all received three cycles of paclitaxel and carboplatin neoadjuvant chemotherapy. According to the curative effect, the patients were divided into effective group and ineffective group. The levels of serum OPN, TK1 and FGFR4 were detected before chemotherapy, and the differences of the above indexes between the two groups were compared. The related data were collected, and the influencing factors of neoadjuvant chemotherapy in patients with LACC were analyzed by multivariate Logistic regression. The predictive value of OPN, TK1 and FGFR4 on the efficacy of neoadjuvant chemotherapy was analyzed by receiver operating characteristic (ROC) curve. Results: All 160 patients successfully completed neoadjuvant chemotherapy, with effective treatment in 129 cases (effective group), and ineffective treatment in 31 cases (ineffective group). The levels of serum OPN, TK1 and FGFR4 in ineffective group were higher than those in effective group (P<0.05). Multivariate Logistic regression analysis showed that FIGO stage Ⅲ, IVA and the high levels of serum OPN, TK1 and FGFR4 were the risk factors affecting the efficacy of neoadjuvant chemotherapy in patients with LACC (P<0.05). The areas under the ROC curve of serum OPN, TK1 and FGFR4 in predicting the efficacy of neoadjuvant chemotherapy in patients with LACC were 0.831, 0.695 and 0.767 respectively, and the areas under the curve predicted by the combination of three items were 0.893, which was higher than that detected by each index alone. Conclusion: The efficacy of neoadjuvant chemotherapy in patients with LACC is affected by FIGO stage and the levels of serum OPN, TK1 and FGFR4. Combined detection of the levels of serum OPN, TK1 and FGFR4 has a certain predictive value for the efficacy of neoadjuvant chemotherapy in patients with LACC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
